<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Acta Pharmacol Sin</journal-id>
    <journal-id journal-id-type="iso-abbrev">Acta Pharmacol Sin</journal-id>
    <journal-title-group>
      <journal-title>Acta Pharmacologica Sinica</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1671-4083</issn>
    <issn pub-type="epub">1745-7254</issn>
    <publisher>
      <publisher-name>Springer Nature Singapore</publisher-name>
      <publisher-loc>Singapore</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9549438</article-id>
    <article-id pub-id-type="pmid">36216900</article-id>
    <article-id pub-id-type="publisher-id">996</article-id>
    <article-id pub-id-type="doi">10.1038/s41401-022-00996-2</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>DrugRep: an automatic virtual screening server for drug repurposing</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Gan</surname>
          <given-names>Jian-hong</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Ji-xiang</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Yang</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Shu-wen</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Dai</surname>
          <given-names>Wen-tao</given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xiao</surname>
          <given-names>Zhi-Xiong</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Cao</surname>
          <given-names>Yang</given-names>
        </name>
        <address>
          <email>cao@scu.edu.cn</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>Center of Growth, Metabolism and Aging, Key Laboratory of Bio-Resource and Eco-Environment of Ministry of Education, College of Life Sciences, </institution><institution>Sichuan University, </institution></institution-wrap>Chengdu, 610065 China </aff>
      <aff id="Aff2"><label>2</label>Shanghai Engineering Research Center of Pharmaceutical Translation, Shanghai, 201203 China </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>State Key Laboratory of Biotherapy and Cancer Center, </institution><institution>Sichuan University, </institution></institution-wrap>Chengdu, 610065 China </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>NHC Key Lab of Reproduction Regulation (Shanghai Institute for Biomedical and Pharmaceutical Technologies), </institution><institution>Fudan University, </institution></institution-wrap>Shanghai, 200032 China </aff>
      <aff id="Aff5"><label>5</label>Animal Disease Prevention and Food Safety Key Laboratory of Sichuan Province, Microbiology and Metabolic Engineering Key Laboratory of Sichuan Province, Chengdu, 610065 China </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>10</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <month>4</month>
      <year>2023</year>
    </pub-date>
    <volume>44</volume>
    <issue>4</issue>
    <fpage>888</fpage>
    <lpage>896</lpage>
    <history>
      <date date-type="received">
        <day>2</day>
        <month>6</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>2</day>
        <month>9</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</copyright-statement>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">Computationally identifying new targets for existing drugs has drawn much attention in drug repurposing due to its advantages over de novo drugs, including low risk, low costs, and rapid pace. To facilitate the drug repurposing computation, we constructed an automated and parameter-free virtual screening server, namely DrugRep, which performed molecular 3D structure construction, binding pocket prediction, docking, similarity comparison and binding affinity screening in a fully automatic manner. DrugRep repurposed drugs not only by receptor-based screening but also by ligand-based screening. The former automatically detected possible binding pockets of the receptor with our cavity detection approach, and then performed batch docking over drugs with a widespread docking program, AutoDock Vina. The latter explored drugs using seven well-established similarity measuring tools, including our recently developed ligand-similarity-based methods LigMate and FitDock. DrugRep utilized easy-to-use graphic interfaces for the user operation, and offered interactive predictions with state-of-the-art accuracy. We expect that this freely available online drug repurposing tool could be beneficial to the drug discovery community. The web site is <ext-link ext-link-type="uri" xlink:href="http://cao.labshare.cn/drugrep/">http://cao.labshare.cn/drugrep/</ext-link>.</p>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>computer-aided drug discovery</kwd>
      <kwd>drug repurposing</kwd>
      <kwd>molecular docking simulation</kwd>
      <kwd>virtual screening</kwd>
    </kwd-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society 2023</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1" sec-type="introduction">
    <title>Introduction</title>
    <p id="Par2">Drug repurposing is a strategy to identify new uses or indications of existing drugs that are beyond the scope of the original medical indication [<xref ref-type="bibr" rid="CR1">1</xref>]. In recent years, the demand for drug repurposing has dramatically increased due to the remarkable advantages over developing de novo drugs, including low risk, low costs, and rapid pace [<xref ref-type="bibr" rid="CR2">2</xref>]. A statistics analysis showed that drug repurposing may save up to 5–7 years in average drug development time [<xref ref-type="bibr" rid="CR1">1</xref>]. To date, numerous successful examples of drug repurposing have been derived. For example, Gleevec, a drug for chronic myeloid leukemia (CML) can also be used to treat patients with malignant gastrointestinal stromal tumors (GIST) [<xref ref-type="bibr" rid="CR3">3</xref>]. And aspirin, an orally administered non-steroidal anti-inflammatory agent, is applied to prevent cardiovascular disease and colorectal cancer [<xref ref-type="bibr" rid="CR4">4</xref>]. Especially, we have witnessed that a number of computational drug repurposing approaches have been applied to fight against COVID-19 [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR8">8</xref>].</p>
    <p id="Par3">Systematic drug repurposing can be largely divided into experimental screening approaches, and in silico approaches. The former depends on particularly designed high-throughput assays, while the latter employs existing data and evolving computational approaches that are remarkably less expensive than the former [<xref ref-type="bibr" rid="CR9">9</xref>]. Among them, virtual screening is a promising Computer-Aided Drug Design (CADD) technology used in drug discovery to search compound libraries in a limited time [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. In general, virtual screening methods are classified as receptor-based screening (also known as structure-based screening or target-based screening) and ligand-based screening. The receptor-based screening typically explores the affinity of each compound in the compound library to the target protein using molecular docking algorithms based on conformational search and scoring functions. This process consists of preparing chemical libraries, identifying binding pockets, establishing docking parameters, executing docking programs and analyzing the results. Nowadays, the tools such as Pocket [<xref ref-type="bibr" rid="CR12">12</xref>], eFindSite [<xref ref-type="bibr" rid="CR13">13</xref>], CavityPlus [<xref ref-type="bibr" rid="CR14">14</xref>] and COACH [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] are available for binding site detection, while GOLD [<xref ref-type="bibr" rid="CR17">17</xref>], Glide [<xref ref-type="bibr" rid="CR18">18</xref>], AutoDock Vina [<xref ref-type="bibr" rid="CR19">19</xref>], DOCK 6 [<xref ref-type="bibr" rid="CR20">20</xref>], SwissDock [<xref ref-type="bibr" rid="CR21">21</xref>], Edock [<xref ref-type="bibr" rid="CR22">22</xref>] and CovalentDock Cloud [<xref ref-type="bibr" rid="CR23">23</xref>] can be used for protein-ligand docking. Unlike the receptor-based screening that indispensably depends on the 3D structure of the receptor, the ligand-based virtual screening searches for new compounds sharing the similar characteristics observed in the known active compounds. Commonly employed similarity assessment methods currently include MACSS [<xref ref-type="bibr" rid="CR24">24</xref>], Open Babel FP2 [<xref ref-type="bibr" rid="CR25">25</xref>], RDKit Morgan fingerprint [<xref ref-type="bibr" rid="CR26">26</xref>], 3D similarity [<xref ref-type="bibr" rid="CR27">27</xref>], etc. With the above principles and methods in mind, several virtual screening tools have been developed. For example, DOCK Blaster [<xref ref-type="bibr" rid="CR28">28</xref>], VSdocker [<xref ref-type="bibr" rid="CR29">29</xref>], iScreen [<xref ref-type="bibr" rid="CR30">30</xref>], and MTiOpenScreen [<xref ref-type="bibr" rid="CR31">31</xref>] are receptor-based virtual screening tools. PoLi [<xref ref-type="bibr" rid="CR32">32</xref>], LiSiCA [<xref ref-type="bibr" rid="CR33">33</xref>], SwissSimilarity [<xref ref-type="bibr" rid="CR34">34</xref>], HybridSim-VS [<xref ref-type="bibr" rid="CR35">35</xref>], and Ligity [<xref ref-type="bibr" rid="CR36">36</xref>] are ligand-based virtual screening tools. However, most of those tools are designed for the general purpose of virtual screening but not well organized for drug repurposing. In particular, these receptor-based tools need to provide complex parameters before screening, such as the grid center coordinates and the sizes of the search space, which are difficult to obtain for non-specialists.</p>
    <p id="Par4">To address these issues with the state-of-the-art technologies, we collected three drug libraries for drug repurposing, including approved drug library, experimental drug library and traditional Chinese medicine library, and then created an automated and parameter-free tool named DrugRep, which can perform receptor-based and ligand-based virtual screening over the carefully organized drug libraries. In our tool, several innovative works developed in-house are efficiently integrated, and those include the structure-based-cavity-detection approach, CurPocket [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], for receptor-based screening, the ligand-similarity-based method, LigMate [<xref ref-type="bibr" rid="CR39">39</xref>], and the hierarchical multi-feature alignment approach, FitDock [<xref ref-type="bibr" rid="CR40">40</xref>], for ligand-based virtual screening. Among them, CurPocket is a protein-ligand binding site prediction method that searches for cavities on the protein surface by calculating curvature factors. Our previous work has demonstrated that it is highly accurate in determining docking boxes for molecular docking [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. LigMate and FitDock both can benefit ligand-based virtual screening [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. The former combines various descriptors in different dimensions of the molecule, while the latter uses a hierarchical alignment approach to find equivalent atom pairs. Our benchmark tests showed that these two achieved more substantial enrichment power than other methods. With the state-of-the-art virtual screening methods as well as the user-friendly interface, DrugRep could serve as a convenient tool for the drug-design community at <ext-link ext-link-type="uri" xlink:href="http://cao.labshare.cn/drugrep/">http://cao.labshare.cn/drugrep/</ext-link>.</p>
  </sec>
  <sec id="Sec2" sec-type="materials|methods">
    <title>Materials and methods</title>
    <sec id="Sec3">
      <title>Workflow</title>
      <p id="Par5">The DrugRep web interface is built by the HTML5, CSS3, PHP, and JavaScript libraries for the client-side user interface. It offers two strategies for drug repurposing, namely Receptor-based Screen (RBS), and Ligand-based Screen (LBS) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). For a protein receptor, RBS applies a novel cavity detection approach to automatically search the possible binding pockets and the results are shown interactively in 3D viewer for users to select. In addition to predictive pockets, RBS also utilizes the co-crystallized ligand from PDBbind [<xref ref-type="bibr" rid="CR43">43</xref>] or user-uploaded ligand to calculate the center and sizes of the docking box using AutoDockTools [<xref ref-type="bibr" rid="CR44">44</xref>] and eBoxSize [<xref ref-type="bibr" rid="CR45">45</xref>]. After determining the docking parameters, RBS then performs docking for each drug with the receptor via the prevalent docking program AutoDock Vina (version 1.1.2) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR46">46</xref>], and finally gets a ranking based on the predicted affinity. For ligand-based virtual screening, LBS measures the similarity between the submitted ligand and each drug in drug libraries by LigMate, FitDock as well as five universal similarity measuring tools (i.e. Morgan fingerprint, LSalign-Rigid, LSalign-Flexi [<xref ref-type="bibr" rid="CR27">27</xref>], FP2 and FP4 [<xref ref-type="bibr" rid="CR25">25</xref>]). Ligand-Screen’s score ranges from 0 to 1.00, where 1.00 means totally same and 0 means not similar at all. The top-ranking compounds obtained by RBS or LBS will be displayed in tables, 2D and 3D images. The 3D visualization service is supported by NGL Viewers [<xref ref-type="bibr" rid="CR47">47</xref>] and the superposition between the submitted ligand and drug is calculated by FitDock.<fig id="Fig1"><label>Fig. 1</label><caption><p>The workflow of DrugRep.</p></caption><graphic xlink:href="41401_2022_996_Fig1_HTML" id="d32e500"/></fig></p>
    </sec>
    <sec id="Sec4">
      <title>Drug libraries</title>
      <p id="Par6">DrugRep offers three drug libraries, including approved drug library (2315 drugs), experimental drug library (5935 drugs) and traditional Chinese medicine library (2390 drugs). The first two are the approved and experimental drugs from DrugBank database (version 5.1.7) [<xref ref-type="bibr" rid="CR48">48</xref>], a state-of-the-art collection of approved, experimental, and pre-clinical drugs. Traditional Chinese medicine library which is from Topscience Company, contains 2390 monomer compounds from nearly 800 traditional Chinese medicines, and includes various structural types such as flavonoids, alkaloids, terpenoids, and glycosides. These drugs were double-checked using Open Babel [<xref ref-type="bibr" rid="CR25">25</xref>] and assigned initial 3D conformations for drugs without 3D conformation using RDKit (<ext-link ext-link-type="uri" xlink:href="http://rdkit.org">http://rdkit.org</ext-link>) and Open Babel. Open Babel is also used to convert all drugs into the PDBQT format required for docking and other format (MOL/MOL2/SDF/SVG) required for similarity measuring tools.</p>
    </sec>
    <sec id="Sec5">
      <title>Benchmark test</title>
      <p id="Par7">DUD [<xref ref-type="bibr" rid="CR49">49</xref>], a well-established virtual screening benchmark dataset, contains 40 protein targets with 98,266 active compounds and decoys. DUD-E [<xref ref-type="bibr" rid="CR50">50</xref>] is an enhanced DUD dataset which contains 102 targets with diverse ligands as well as decoys. The maximum unbiased validation (MUV) dataset [<xref ref-type="bibr" rid="CR51">51</xref>] contains 17 targets, and each target has 30 actives and 15,000 decoys, which are unbiased in terms of simulation bias and artificial enrichment.</p>
      <p id="Par8">The enrichment testing is often used to evaluate virtual screening performance, and its result will be shown by the receiver operating characteristic (ROC) curve [<xref ref-type="bibr" rid="CR52">52</xref>]. For all attainable score thresholds going from the best score to the worst, the selectivity (Se) and specificity (Sp) were calculated, as given by<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{{\mathrm{Se}}}}}}}} = \frac{{{{{{{{{\mathrm{TP}}}}}}}}}}{{{{{{{{{\mathrm{TP}}}}}}}} + {{{{{{{\mathrm{FN}}}}}}}}}}$$\end{document}</tex-math><mml:math id="M2"><mml:mi mathvariant="normal">Se</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">TP</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">TP</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FN</mml:mi></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="41401_2022_996_Article_Equa.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equb"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{{\mathrm{Sp}}}}}}}} = \frac{{{{{{{{{\mathrm{TN}}}}}}}}}}{{{{{{{{{\mathrm{TN}}}}}}}} + {{{{{{{\mathrm{FP}}}}}}}}}}$$\end{document}</tex-math><mml:math id="M4"><mml:mi mathvariant="normal">Sp</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">TN</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">TN</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">FP</mml:mi></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="41401_2022_996_Article_Equb.gif" position="anchor"/></alternatives></disp-formula>Where TP is the true positive, FN is the false negative, TN is the true negative, and FP is the false positive. The ROC curve was then graphed by plotting all pairs of (1-Sp, Se). The area under the curve (AUC), which ranges from 0 to 1, is the metric used to assess a ROC curve. To be specific, AUC = 0.5 indicates that the compounds are randomly ranked, and the higher AUC means that the performance is better.</p>
      <p id="Par9">Enrichment Factor (EF), defined by the ratio of true positives in the first percent (TP<sub>1%</sub>) to all cases (N<sub>1%</sub>) divided by the ratio of actives (N<sub>a</sub>) to the total number (N<sub>t</sub>) of test cases, is another metric used to evaluate enrichment testing.<disp-formula id="Equc"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{{{\mathrm{EF}}}}}}}}_{1{{{{{{{\mathrm{\% }}}}}}}}} = \frac{{{{{{{{{\mathrm{TP}}}}}}}}_{1{{{{{{{\mathrm{\% }}}}}}}}}/{{{{{{{\mathrm{N}}}}}}}}_{1{{{{{{{\mathrm{\% }}}}}}}}}}}{{{{{{{{{\mathrm{N}}}}}}}}_{{{{{{{\mathrm{a}}}}}}}}/{{{{{{{\mathrm{N}}}}}}}}_{{{{{{{\mathrm{t}}}}}}}}}}$$\end{document}</tex-math><mml:math id="M6"><mml:msub><mml:mrow><mml:mi mathvariant="normal">EF</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">TP</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="41401_2022_996_Article_Equc.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par10">EF greater than 1 indicates the compounds are not randomly selected, and higher EF means the enrichment effect is more significant.</p>
    </sec>
  </sec>
  <sec id="Sec6" sec-type="results">
    <title>Results</title>
    <sec id="Sec7">
      <title>Performance of RBS</title>
      <p id="Par11">DrugRep is a parameter-free virtual screening tool, which is able to automatically determine the docking box for RBS. To test the feasibility and accuracy of the receptor-based virtual screening, we performed enrichment tests using the targets (ACHE, AR, COX-2, DHFR, MR, P38, PDGFrb, SAHH, SRC) from DUD dataset, which have been benchmarked in Vina-based virtual screening by Durrant [<xref ref-type="bibr" rid="CR53">53</xref>]. For comparison, we also performed the same test using the docking box obtained from the co-crystallized ligand (named DrugRep-xtal), since it is the near optimal parameters for screening [<xref ref-type="bibr" rid="CR45">45</xref>]. The results show that DrugRep achieved an average AUC values of 0.69, which is superior to 0.66 by Durrant and closed to 0.74 by DrugRep-xtal (Table <xref rid="Tab1" ref-type="table">1</xref> and Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Particularly, it outperforms the latter in 5 of the 9 targets, indicating that DrugRep is better than the virtual screening with manually-determined docking boxes, and even comparable to the virtual screening with the co-crystallized-structure-determined docking boxes. We also calculated the EF1 and EF5 (EF for top 1% and top 5%), which are more important metrics for the actual virtual screening researches. As shown in Table <xref rid="Tab1" ref-type="table">1</xref>, the average EF1 and EF5 of DrugRep reach 12.25 and 6.18, which are almost the same to 11.94 and 6.38 by DrugRep-xtal. Particularly, the EF1 of AR and SAHH are 19.79 and 26.84, respectively, outperforming 13.78 and 14.92 by DrugRep-xtal significantly. Detailed analysis shows that the predicted docking boxes by DrugRep are usually slightly larger than the docking boxes of DrugRep-xtal, resulting in increased accuracy for some targets. However, in a few cases, the predicted docking boxes may shift a little such as COX-2 (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>) and PDGFrb, and the predicted docking boxes are too big such as MR. Both result in reduced accuracy. We also benchmarked DrugRep using another popular dataset of DUD-E. The result shows that DrugRep achieves comparable performance to the state-of-the-art approach (Supplementary Table <xref rid="MOESM1" ref-type="media">S3</xref>). Overall, these results indicate that the automatic RBS by DrugRep is feasible and accurate for drug repurposing in many targets, and its unique parameter-free manner is highly convenient for the non-expert users.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Enrichment tests using DUD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Target</th><th colspan="3">AUC</th><th colspan="2">EF1</th><th colspan="2">EF5</th></tr><tr><th>Vina<sup>a</sup></th><th>DrugRep-xtal</th><th>DrugRep</th><th>DrugRep-xtal</th><th>DrugRep</th><th>DrugRep-xtal</th><th>DrugRep</th></tr></thead><tbody><tr><td>ACHE</td><td>0.67</td><td>0.65</td><td>0.67</td><td>1.86</td><td>5.6</td><td>3.17</td><td>4.86</td></tr><tr><td>AR</td><td>0.81</td><td>0.77</td><td>0.8</td><td>13.78</td><td>19.79</td><td>9.09</td><td>11.36</td></tr><tr><td>COX-2</td><td>0.31</td><td>0.89</td><td>0.79</td><td>26.12</td><td>24.49</td><td>13.61</td><td>10.89</td></tr><tr><td>DHFR</td><td>0.76</td><td>0.79</td><td>0.85</td><td>9.24</td><td>10.7</td><td>4.58</td><td>7.66</td></tr><tr><td>MR</td><td>0.84</td><td>0.82</td><td>0.54</td><td>31</td><td>12.38</td><td>13.15</td><td>2.63</td></tr><tr><td>P38</td><td>0.54</td><td>0.62</td><td>0.63</td><td>1.54</td><td>2.2</td><td>2.95</td><td>2.69</td></tr><tr><td>PDGFrb</td><td>0.53</td><td>0.69</td><td>0.45</td><td>5.83</td><td>7</td><td>1.17</td><td>2.35</td></tr><tr><td>SAHH</td><td>0.76</td><td>0.74</td><td>0.85</td><td>14.92</td><td>26.84</td><td>6.66</td><td>10.89</td></tr><tr><td>SRC</td><td>0.69</td><td>0.69</td><td>0.62</td><td>3.13</td><td>1.25</td><td>3.01</td><td>2.26</td></tr><tr><td>AVE.</td><td>0.66</td><td>0.74</td><td>0.69</td><td>11.94</td><td>12.25</td><td>6.38</td><td>6.18</td></tr></tbody></table><table-wrap-foot><p>DrugRep-xtal means virtual screening using calculated pockets by crystal ligand. DrugRep means virtual screening using predicted pockets by CurPocket.</p><p><sup>a</sup>The data were from Durrant, J.D., 2011 [<xref ref-type="bibr" rid="CR53">53</xref>].</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><title>ROC curves of virtual screening results for 9 protein targets using DrugRep.</title><p>The dashed line indicates random selection of compounds.</p></caption><graphic xlink:href="41401_2022_996_Fig2_HTML" id="d32e1009"/></fig></p>
    </sec>
    <sec id="Sec8">
      <title>Performance of LBS</title>
      <p id="Par12">We then tested the performance of DrugRep on ligand-based virtual screening. We calculated the AUC value and the EF1 value for randomly selected actives with all corresponding decoys and the remaining actives on each target on the MUV dataset. The results of these calculations are fused using the maximum value. For each target, the above procedure was repeated 100 times to reduce the impact of randomness [<xref ref-type="bibr" rid="CR39">39</xref>]. Figure <xref rid="Fig3" ref-type="fig">3a and b</xref> show the average AUC value and EF1 value of different methods for MUV dataset, respectively. The two histograms indicate LigMate surpasses all other methods. Further, we analyzed each target independently on the MUV dataset. As shown in Fig. <xref rid="Fig3" ref-type="fig">3c and d</xref>, LigMate achieves EF1s above 30 for targets including Cathepsin G, FXIIa, FXIa and PKA, which is significantly higher than those of most control methods. For the remaining targets, LigMate shows a comparable or even better performance. At the same time, we observed that other methods showed excellent performance for some targets (Supplementary Table <xref rid="MOESM1" ref-type="media">S4</xref> and <xref rid="MOESM1" ref-type="media">S5</xref>). For example, FitDock has the highest EF1 value of 7.70 for HIVRT-RNase and the highest AUC value of 0.66 for S1P1rec. FP2 had the highest EF1 value of 19.15, 52.65, and 3.95 against Rho-Kinase2, CathepsinG, and M1rec. FP4 had the highest AUC values of 0.63, 0.71 for ER-β-Coact.Bind.Inh. and ER-α-Coact.Bind.Pot. Morgan Fingerprint achieves the highest EF1 values for FAK and D1rec., which were 13.25, 15.55; and has the highest AUC values for PKA, SF1 Inh., Rho-Kinase2, M1rec., which were 0.83, 0.70, 0.76, 0.58. Taken together, we argue that LigMate, FitDock, and other methods provided by DrugRep are complementary in enrichment test, and can contribute to ligand-based virtual screening.<fig id="Fig3"><label>Fig. 3</label><caption><title>Benchmark results of LigMate and FitDock compared to the control methods.</title><p><bold>a</bold>, <bold>b</bold> show the average EF1 and AUC for the MUV datasets, respectively. <bold>c</bold>, <bold>d</bold> show the AUC and the EF1 for each of the 17 targets from the MUV dataset, respectively. The x-axis shows the different methods, while the y-axis shows the AUC value in (<bold>a</bold>, <bold>c</bold>), and the EF1 value in (<bold>b</bold>, <bold>d</bold>).</p></caption><graphic xlink:href="41401_2022_996_Fig3_HTML" id="d32e1065"/></fig></p>
    </sec>
    <sec id="Sec9">
      <title>Case study with DrugRep</title>
      <p id="Par13">COX-2 that plays a significant role in conversion of arachidonate to prostaglandin H2 is key in the inflammatory response [<xref ref-type="bibr" rid="CR54">54</xref>]. Targeted inhibition of COX-2’s activity can reduce the risk of peptic ulcer and is the main feature of nonsteroidal anti-inflammatory drug (NSAID) including aspirin, flurbiprofen, ibuprofen, celecoxib, flufenamic, mefenamic and tolfenamic acids [<xref ref-type="bibr" rid="CR55">55</xref>]. Some COX-2 inhibitors may cause a significant increasing risk in heart attacks and strokes from clinical trials [<xref ref-type="bibr" rid="CR56">56</xref>]. Therefore, screening the approved drugs which may bind with COX-2 is a general strategy in drug repurposing. Taking the screening of COX-2 with RBS as an example (Fig. <xref rid="Fig4" ref-type="fig">4</xref>), we only need to perform a few simple steps on the DrugRep web server, as follows: (i) uploading the target protein, (ii) detecting and selecting the pocket, (iii) submitting the task, and (iv) viewing the results of RBS. Five of the 30 best-scored drugs, namely celecoxib, oxaprozin, bendazac, meclofenamic acid and phenylbutazone, are associated with COX-2 (Fig. <xref rid="Fig5" ref-type="fig">5a</xref>). Of the drugs above, celecoxib, oxaprozin, meclofenamic acid and phenylbutazone are known inhibitors of COX-2. When inspecting the top 50 best-scored drugs, drug thalidomide (DrugBank ID: DB01041) that can be bioactivated by COX-2 [<xref ref-type="bibr" rid="CR57">57</xref>] would also be found. Thalidomide is a typical example of drug repurposing. It was developed initially against morning sickness in pregnant women, but it was withdrawn years later because of its side effect of leading to severe congenital disabilities in children. Recently, researchers notice that thalidomide can also be adopted to treat some other diseases, such as leprosy, multiple myeloma, Crohn’s disease and HIV [<xref ref-type="bibr" rid="CR58">58</xref>]. In addition, we also performed LBS against COX-2’s co-crystallized ligand using seven LBS methods embedded in DrugRep. For a drug with different scores by different LBS methods, the maximum score was adopted. Among the 50 drugs with the highest scores, five drugs, namely celecoxib, parecoxib, Etoricoxib, rofecoxib and valdecoxib (Fig. <xref rid="Fig5" ref-type="fig">5b</xref> and Supplementary Table <xref rid="MOESM1" ref-type="media">S6</xref>), are known inhibitors of COX-2 and share similarities with the query ligand greater than 0.7. Among these drugs screened, celecoxib gets a similarity score of 0.971 by LBS, and gets an affinity score of −10.8 by RBS, which is greater than the co-crystallized ligand’s score of −10.2. As is shown Fig. <xref rid="Fig5" ref-type="fig">5c</xref>, celecoxib get an extra hydrophobic contact in a hydrophobic cavity formed by Phe381, Leu384, Tyr 385, Trp 387, Phe 513 and Ser530, because of a substitution of the bromophenyl ring to the methylbenzene ring. Example of COX-2 suggests that DrugRep can be used to screen new drugs for target, as well as to observe drug-target binding patterns.<fig id="Fig4"><label>Fig. 4</label><caption><title>The operation process on the web page by RBS.</title><p>The process includes (1) uploading the target protein, (2) detecting and selecting the pocket, (3) submitting the task, and (4) viewing the results of RBS.</p></caption><graphic xlink:href="41401_2022_996_Fig4_HTML" id="d32e1112"/></fig><fig id="Fig5"><label>Fig. 5</label><caption><title>The screening result of COX-2.</title><p><bold>a</bold> shows 2D structures of five screened drugs truly binding to the COX-2 using RBS. The score after the ID means the affinity score (kcal/mol). <bold>b</bold> shows 2D structures of COX-2 co-crystallized ligand and nine screened drugs truly binding to the COX-2 using LBS. The score after the ID means the maximum similarity score. <bold>c</bold> shows contact residues and interaction forces of COX-2’s ligand and celecoxib including hydrogen bond (color skyblue), weak hydrogen bond (color smudge), and hydrophobic contact (color lightblue).</p></caption><graphic xlink:href="41401_2022_996_Fig5_HTML" id="d32e1132"/></fig></p>
    </sec>
  </sec>
  <sec id="Sec10" sec-type="discussion">
    <title>Discussion</title>
    <p id="Par14">New drug discovery is time-consuming and costly. Computational drug repurposing provides the possibility to improve this situation, and has a promising potential in modern drug development. However, computational tasks such as preparing chemical libraries, identifying binding pockets, evaluating docking parameters, and executing docking procedures can be cumbersome for the researcher. Here, we constructed an automated and parameter-free tool called DrugRep for drug repurposing. Our efforts can be summarized into four aspects. Firstly, DrugRep is designed for the purpose of drug repurposing with well-organized drug databases including approved or experimental-stage chemical drugs, and traditional Chinese medicine drugs. Secondly, DrugRep performs large-scale RBS based on CurPocket and AutoDock Vina. CurPocket for pocket recognition achieves a success rate of 70% in predicting the top 1 docking pockets and 92.5% in top 5 on the DUD dataset (Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>), making it accurate and convenient to prepare docking parameters. Thirdly, compared to receptor-based screening where docking of a large number of drugs takes a certain amount of time, DrugRep provides ligand-based screening based on our latest developed LigMate and FitDock as well as other well-established similarity measuring tools, helping to discover pharmacophores and assisting molecular optimization. Finally, DrugRep offers user-friendly interface that allows even non-expert users to perform drug repurposing and visualize results with abundant information, such as 3D interactive view, 2D images, the molecular mass, the number of hydrogen bond donors, the number of hydrogen bond acceptors, and the number of rotatable bonds, the n-octanol-water partition coefficient (logP), drug targets, drug pharmacodynamics, hyperlinks to the related data [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR59">59</xref>] and so on.</p>
    <p id="Par15">Despite the successful performance in the benchmark tests, DrugRep also showed some limitations, such as false positive predictions. It can be attributed to the reasons below. Firstly, proteins may adopt various binding conformations, while the RBS of DrugRep performs docking with a static structure, which is artificial and harmful to some screening. For example, a highly flexible receptor, namely HSP90 [<xref ref-type="bibr" rid="CR60">60</xref>], showed 0 for both EF1 and EF5 in the benchmark (Supplementary Table <xref rid="MOESM1" ref-type="media">S2</xref>). Secondly, how to rank the results of screening remains an open question, particularly for enriching low affinity actives (i.e. TK [<xref ref-type="bibr" rid="CR61">61</xref>]). DrugRep employs Vina score and X-Score [<xref ref-type="bibr" rid="CR62">62</xref>] to evaluate the binding modes, which shows the advantages and disadvantages of each (Supplementary Table <xref rid="MOESM1" ref-type="media">S2</xref>). Still, there are much room for further improvement. Thirdly, the data-driven methods, such as machine learning for docking or AI-based protein-ligand binding prediction, have shown promising results [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR63">63</xref>–<xref ref-type="bibr" rid="CR65">65</xref>]. The current DrugRep has not taken advantages of those state-of-the-art methods. Fourthly, in LBS, the scores of the seven similarity measuring methods usually are inconsistent with each other due to different scoring criteria. It may be not easy for the users to select the best prediction. Take Cox-2 as an example, parecoxib (DB08439) has a score of 0.731 in Flexi-LS-align, 0.71 in Rigid-LS-align and 0.688 in FitDock, but 0.473 in FP4 and 0.297 in Morgan fingerprint (Supplementary Table <xref rid="MOESM1" ref-type="media">S6</xref>). Finally, in terms of time cost, Flexi-LS-align and FitDock take more time (20 min) than other methods because of flexible structure comparison. And RBS is time-consuming as it takes about three hours or even more for 2000 drugs with a 500 aa-length protein on our server.</p>
    <p id="Par16">In the future, we plan to develop methods for receptor optimization and docking parameters optimization before the docking screen, improving the docking and scoring by incorporating the AI-based methods, integrating the similarity scores in LBS with a more convenient ranking system, and optimizing the algorithms and pipelines to accelerate the computation by the guidance of existing similar co-crystal structures and the introduction of GPU-based Vina docking [<xref ref-type="bibr" rid="CR66">66</xref>]. Overall, DrugRep will be more accurate, clever, easy-to-use and rapid for drug repurposing with our continuous efforts.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary information</title>
    <sec id="Sec11">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="41401_2022_996_MOESM1_ESM.pdf">
            <caption>
              <p>Supplementary Information</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <sec>
    <title>Supplementary information</title>
    <p>The online version contains supplementary material available at 10.1038/s41401-022-00996-2.</p>
  </sec>
  <ack>
    <title>Acknowledgements</title>
    <p>This work was supported by the National Natural Science Foundation of China (81973243, 31401130, and 81830108). The authors wish to thank Dr. Maximilian Grimm for his kind help in constructing the web server.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Author contributions</title>
    <p>JHG built the DrugRep web server and wrote the manuscript. JXL built the DrugRep web server and benchmarked the program. YL and SWC tested the server. SWC revised the manuscript. WTD designed the project. ZXX guided experiments. YC designed the project and wrote the manuscript.</p>
  </notes>
  <notes id="FPar1" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par17">The authors declare no competing interests.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ashburn</surname>
            <given-names>TT</given-names>
          </name>
          <name>
            <surname>Thor</surname>
            <given-names>KB</given-names>
          </name>
        </person-group>
        <article-title>Drug repositioning: identifying and developing new uses for existing drugs</article-title>
        <source>Nat Rev Drug Discov</source>
        <year>2004</year>
        <volume>3</volume>
        <fpage>673</fpage>
        <lpage>83</lpage>
        <pub-id pub-id-type="doi">10.1038/nrd1468</pub-id>
        <?supplied-pmid 15286734?>
        <pub-id pub-id-type="pmid">15286734</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pushpakom</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Iorio</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Eyers</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Escott</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Hopper</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wells</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Drug repurposing: progress, challenges and recommendations</article-title>
        <source>Nat Rev Drug Discov</source>
        <year>2019</year>
        <volume>18</volume>
        <fpage>41</fpage>
        <lpage>58</lpage>
        <pub-id pub-id-type="doi">10.1038/nrd.2018.168</pub-id>
        <?supplied-pmid 30310233?>
        <pub-id pub-id-type="pmid">30310233</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Druker</surname>
            <given-names>BJ</given-names>
          </name>
        </person-group>
        <article-title>Imatinib as a paradigm of targeted therapies</article-title>
        <source>Adv Cancer Res</source>
        <year>2004</year>
        <volume>91</volume>
        <fpage>1</fpage>
        <lpage>30</lpage>
        <pub-id pub-id-type="doi">10.1016/S0065-230X(04)91001-9</pub-id>
        <?supplied-pmid 15327887?>
        <pub-id pub-id-type="pmid">15327887</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bibbins-Domingo</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement</article-title>
        <source>Ann Intern Med</source>
        <year>2016</year>
        <volume>164</volume>
        <fpage>836</fpage>
        <lpage>45</lpage>
        <pub-id pub-id-type="doi">10.7326/M16-0577</pub-id>
        <?supplied-pmid 27064677?>
        <pub-id pub-id-type="pmid">27064677</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dotolo</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Marabotti</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Facchiano</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tagliaferri</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>A review on drug repurposing applicable to COVID-19</article-title>
        <source>Brief Bioinform</source>
        <year>2021</year>
        <volume>22</volume>
        <fpage>726</fpage>
        <lpage>41</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbaa288</pub-id>
        <?supplied-pmid 33147623?>
        <pub-id pub-id-type="pmid">33147623</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fan</surname>
            <given-names>HH</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>LQ</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>WL</given-names>
          </name>
          <name>
            <surname>An</surname>
            <given-names>XP</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>ZD</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>XQ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model</article-title>
        <source>Chin Med J (Engl)</source>
        <year>2020</year>
        <volume>133</volume>
        <fpage>1051</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1097/CM9.0000000000000797</pub-id>
        <?supplied-pmid 32149769?>
        <pub-id pub-id-type="pmid">32149769</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rothan</surname>
            <given-names>HA</given-names>
          </name>
          <name>
            <surname>Byrareddy</surname>
            <given-names>SN</given-names>
          </name>
        </person-group>
        <article-title>The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak</article-title>
        <source>J Autoimmun</source>
        <year>2020</year>
        <volume>109</volume>
        <fpage>102433</fpage>
        <pub-id pub-id-type="doi">10.1016/j.jaut.2020.102433</pub-id>
        <?supplied-pmid 32113704?>
        <pub-id pub-id-type="pmid">32113704</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Gan</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>DrugDevCovid19: an atlas of anti-COVID-19 compounds derived by computer-aided drug design</article-title>
        <source>Molecules</source>
        <year>2022</year>
        <volume>27</volume>
        <fpage>683</fpage>
        <pub-id pub-id-type="doi">10.3390/molecules27030683</pub-id>
        <?supplied-pmid 35163948?>
        <pub-id pub-id-type="pmid">35163948</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cha</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Erez</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Reynolds</surname>
            <given-names>IJ</given-names>
          </name>
          <name>
            <surname>Kumar</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ross</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Koytiger</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Drug repurposing from the perspective of pharmaceutical companies</article-title>
        <source>Br J Pharmacol</source>
        <year>2018</year>
        <volume>175</volume>
        <fpage>168</fpage>
        <lpage>80</lpage>
        <pub-id pub-id-type="doi">10.1111/bph.13798</pub-id>
        <?supplied-pmid 28369768?>
        <pub-id pub-id-type="pmid">28369768</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rester</surname>
            <given-names>U</given-names>
          </name>
        </person-group>
        <article-title>From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective</article-title>
        <source>Curr Opin Drug Discov Devel</source>
        <year>2008</year>
        <volume>11</volume>
        <fpage>559</fpage>
        <lpage>68</lpage>
        <?supplied-pmid 18600572?>
        <pub-id pub-id-type="pmid">18600572</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Maia</surname>
            <given-names>EHB</given-names>
          </name>
          <name>
            <surname>Assis</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>de Oliveira</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>da Silva</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Taranto</surname>
            <given-names>AG</given-names>
          </name>
        </person-group>
        <article-title>Structure-based virtual screening: from classical to artificial intelligence</article-title>
        <source>Front Chem</source>
        <year>2020</year>
        <volume>8</volume>
        <fpage>343</fpage>
        <pub-id pub-id-type="doi">10.3389/fchem.2020.00343</pub-id>
        <?supplied-pmid 32411671?>
        <pub-id pub-id-type="pmid">32411671</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Levitt</surname>
            <given-names>DG</given-names>
          </name>
          <name>
            <surname>Banaszak</surname>
            <given-names>LJ</given-names>
          </name>
        </person-group>
        <article-title>POCKET: a computer graphies method for identifying and displaying protein cavities and their surrounding amino acids</article-title>
        <source>J Mol Graph</source>
        <year>1992</year>
        <volume>10</volume>
        <fpage>229</fpage>
        <lpage>34</lpage>
        <pub-id pub-id-type="doi">10.1016/0263-7855(92)80074-N</pub-id>
        <?supplied-pmid 1476996?>
        <pub-id pub-id-type="pmid">1476996</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Brylinski</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Feinstein</surname>
            <given-names>WP</given-names>
          </name>
        </person-group>
        <article-title>eFindSite: improved prediction of ligand binding sites in protein models using meta-threading, machine learning and auxiliary ligands</article-title>
        <source>J Comput Aided Mol Des</source>
        <year>2013</year>
        <volume>27</volume>
        <fpage>551</fpage>
        <lpage>67</lpage>
        <pub-id pub-id-type="doi">10.1007/s10822-013-9663-5</pub-id>
        <?supplied-pmid 23838840?>
        <pub-id pub-id-type="pmid">23838840</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>W</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CavityPlus: a web server for protein cavity detection with pharmacophore modelling, allosteric site identification and covalent ligand binding ability prediction</article-title>
        <source>Nucleic Acids Res</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>W374</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gky380</pub-id>
        <?supplied-pmid 29750256?>
        <pub-id pub-id-type="pmid">29750256</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Peng</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>COACH-D: improved protein-ligand binding sites prediction with refined ligand-binding poses through molecular docking</article-title>
        <source>Nucleic Acids Res</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>W438</fpage>
        <lpage>42</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gky439</pub-id>
        <?supplied-pmid 29846643?>
        <pub-id pub-id-type="pmid">29846643</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Roy</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment</article-title>
        <source>Bioinformatics</source>
        <year>2013</year>
        <volume>29</volume>
        <fpage>2588</fpage>
        <lpage>95</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btt447</pub-id>
        <?supplied-pmid 23975762?>
        <pub-id pub-id-type="pmid">23975762</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Verdonk</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Cole</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Hartshorn</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Murray</surname>
            <given-names>CW</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>RD</given-names>
          </name>
        </person-group>
        <article-title>Improved protein-ligand docking using GOLD</article-title>
        <source>Proteins</source>
        <year>2003</year>
        <volume>52</volume>
        <fpage>609</fpage>
        <lpage>23</lpage>
        <pub-id pub-id-type="doi">10.1002/prot.10465</pub-id>
        <?supplied-pmid 12910460?>
        <pub-id pub-id-type="pmid">12910460</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Friesner</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Banks</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Murphy</surname>
            <given-names>RB</given-names>
          </name>
          <name>
            <surname>Halgren</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Klicic</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Mainz</surname>
            <given-names>DT</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</article-title>
        <source>J Med Chem</source>
        <year>2004</year>
        <volume>47</volume>
        <fpage>1739</fpage>
        <lpage>49</lpage>
        <pub-id pub-id-type="doi">10.1021/jm0306430</pub-id>
        <?supplied-pmid 15027865?>
        <pub-id pub-id-type="pmid">15027865</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Trott</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Olson</surname>
            <given-names>AJ</given-names>
          </name>
        </person-group>
        <article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title>
        <source>J Comput Chem</source>
        <year>2010</year>
        <volume>31</volume>
        <fpage>455</fpage>
        <lpage>61</lpage>
        <?supplied-pmid 19499576?>
        <pub-id pub-id-type="pmid">19499576</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lang</surname>
            <given-names>PT</given-names>
          </name>
          <name>
            <surname>Brozell</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Mukherjee</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pettersen</surname>
            <given-names>EF</given-names>
          </name>
          <name>
            <surname>Meng</surname>
            <given-names>EC</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>V</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DOCK 6: combining techniques to model RNA-small molecule complexes</article-title>
        <source>RNA</source>
        <year>2009</year>
        <volume>15</volume>
        <fpage>1219</fpage>
        <lpage>30</lpage>
        <pub-id pub-id-type="doi">10.1261/rna.1563609</pub-id>
        <?supplied-pmid 19369428?>
        <pub-id pub-id-type="pmid">19369428</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Grosdidier</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Zoete</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Michielin</surname>
            <given-names>O</given-names>
          </name>
        </person-group>
        <article-title>SwissDock, a protein-small molecule docking web service based on EADock DSS</article-title>
        <source>Nucleic Acids Res</source>
        <year>2011</year>
        <volume>39</volume>
        <fpage>W270</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkr366</pub-id>
        <?supplied-pmid 21624888?>
        <pub-id pub-id-type="pmid">21624888</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Bell</surname>
            <given-names>EW</given-names>
          </name>
          <name>
            <surname>Yin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>EDock: blind protein-ligand docking by replica-exchange monte carlo simulation</article-title>
        <source>J Cheminform</source>
        <year>2020</year>
        <volume>12</volume>
        <fpage>37</fpage>
        <pub-id pub-id-type="doi">10.1186/s13321-020-00440-9</pub-id>
        <?supplied-pmid 33430966?>
        <pub-id pub-id-type="pmid">33430966</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ouyang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ge</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kwoh</surname>
            <given-names>CK</given-names>
          </name>
        </person-group>
        <article-title>CovalentDock Cloud: a web server for automated covalent docking</article-title>
        <source>Nucleic Acids Res</source>
        <year>2013</year>
        <volume>41</volume>
        <fpage>W329</fpage>
        <lpage>32</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkt406</pub-id>
        <?supplied-pmid 23677616?>
        <pub-id pub-id-type="pmid">23677616</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Durant</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Leland</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Henry</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Nourse</surname>
            <given-names>JG</given-names>
          </name>
        </person-group>
        <article-title>Reoptimization of MDL keys for use in drug discovery</article-title>
        <source>J Chem Inf Comput Sci</source>
        <year>2002</year>
        <volume>42</volume>
        <fpage>1273</fpage>
        <lpage>80</lpage>
        <pub-id pub-id-type="doi">10.1021/ci010132r</pub-id>
        <?supplied-pmid 12444722?>
        <pub-id pub-id-type="pmid">12444722</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>O’Boyle</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Banck</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>James</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Morley</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Vandermeersch</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Hutchison</surname>
            <given-names>GR</given-names>
          </name>
        </person-group>
        <article-title>Open Babel: an open chemical toolbox</article-title>
        <source>J Cheminform</source>
        <year>2011</year>
        <volume>3</volume>
        <fpage>33</fpage>
        <pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id>
        <?supplied-pmid 21982300?>
        <pub-id pub-id-type="pmid">21982300</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rogers</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hahn</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Extended-connectivity fingerprints</article-title>
        <source>J Chem Inf Model</source>
        <year>2010</year>
        <volume>50</volume>
        <fpage>742</fpage>
        <lpage>54</lpage>
        <pub-id pub-id-type="doi">10.1021/ci100050t</pub-id>
        <?supplied-pmid 20426451?>
        <pub-id pub-id-type="pmid">20426451</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>LS-align: an atom-level, flexible ligand structural alignment algorithm for high-throughput virtual screening</article-title>
        <source>Bioinformatics</source>
        <year>2018</year>
        <volume>34</volume>
        <fpage>2209</fpage>
        <lpage>18</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bty081</pub-id>
        <?supplied-pmid 29462237?>
        <pub-id pub-id-type="pmid">29462237</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Irwin</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Shoichet</surname>
            <given-names>BK</given-names>
          </name>
          <name>
            <surname>Mysinger</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Colizzi</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wassam</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Automated docking screens: a feasibility study</article-title>
        <source>J Med Chem</source>
        <year>2009</year>
        <volume>52</volume>
        <fpage>5712</fpage>
        <lpage>20</lpage>
        <pub-id pub-id-type="doi">10.1021/jm9006966</pub-id>
        <?supplied-pmid 19719084?>
        <pub-id pub-id-type="pmid">19719084</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Prakhov</surname>
            <given-names>ND</given-names>
          </name>
          <name>
            <surname>Chernorudskiy</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Gainullin</surname>
            <given-names>MR</given-names>
          </name>
        </person-group>
        <article-title>VSDocker: a tool for parallel high-throughput virtual screening using AutoDock on Windows-based computer clusters</article-title>
        <source>Bioinformatics</source>
        <year>2010</year>
        <volume>26</volume>
        <fpage>1374</fpage>
        <lpage>5</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btq149</pub-id>
        <?supplied-pmid 20378556?>
        <pub-id pub-id-type="pmid">20378556</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tsai</surname>
            <given-names>TY</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>KW</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>CY</given-names>
          </name>
        </person-group>
        <article-title>iScreen: world’s first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan</article-title>
        <source>J Comput Aided Mol Des</source>
        <year>2011</year>
        <volume>25</volume>
        <fpage>525</fpage>
        <lpage>31</lpage>
        <pub-id pub-id-type="doi">10.1007/s10822-011-9438-9</pub-id>
        <?supplied-pmid 21647737?>
        <pub-id pub-id-type="pmid">21647737</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Labbé</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Rey</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lagorce</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Vavruša</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Becot</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Sperandio</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MTiOpenScreen: a web server for structure-based virtual screening</article-title>
        <source>Nucleic Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <fpage>W448</fpage>
        <lpage>54</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkv306</pub-id>
        <?supplied-pmid 25855812?>
        <pub-id pub-id-type="pmid">25855812</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Roy</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Srinivasan</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Skolnick</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>PoLi: a virtual screening pipeline based on template pocket and ligand similarity</article-title>
        <source>J Chem Inf Model</source>
        <year>2015</year>
        <volume>55</volume>
        <fpage>1757</fpage>
        <lpage>70</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.5b00232</pub-id>
        <?supplied-pmid 26225536?>
        <pub-id pub-id-type="pmid">26225536</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lešnik</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Štular</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Brus</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Knez</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gobec</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Janežič</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>LiSiCA: a software for ligand-based virtual screening and its application for the discovery of butyrylcholinesterase inhibitors</article-title>
        <source>J Chem Inf Model</source>
        <year>2015</year>
        <volume>55</volume>
        <fpage>1521</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.5b00136</pub-id>
        <?supplied-pmid 26158767?>
        <pub-id pub-id-type="pmid">26158767</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zoete</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Daina</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bovigny</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Michielin</surname>
            <given-names>O</given-names>
          </name>
        </person-group>
        <article-title>SwissSimilarity: a web tool for low to ultra high throughput ligand-based virtual screening</article-title>
        <source>J Chem Inf Model</source>
        <year>2016</year>
        <volume>56</volume>
        <fpage>1399</fpage>
        <lpage>404</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.6b00174</pub-id>
        <?supplied-pmid 27391578?>
        <pub-id pub-id-type="pmid">27391578</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Pistolozzi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>HybridSim-VS: a web server for large-scale ligand-based virtual screening using hybrid similarity recognition techniques</article-title>
        <source>Bioinformatics</source>
        <year>2017</year>
        <volume>33</volume>
        <fpage>3480</fpage>
        <lpage>1</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btx418</pub-id>
        <?supplied-pmid 29036579?>
        <pub-id pub-id-type="pmid">29036579</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ebejer</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Finn</surname>
            <given-names>PW</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>WK</given-names>
          </name>
          <name>
            <surname>Deane</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Morris</surname>
            <given-names>GM</given-names>
          </name>
        </person-group>
        <article-title>Ligity: a non-superpositional, knowledge-based approach to virtual screening</article-title>
        <source>J Chem Inf Model</source>
        <year>2019</year>
        <volume>59</volume>
        <fpage>2600</fpage>
        <lpage>16</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00779</pub-id>
        <?supplied-pmid 31117509?>
        <pub-id pub-id-type="pmid">31117509</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Grimm</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>WT</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>ZX</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>CB-Dock: a web server for cavity detection-guided protein-ligand blind docking</article-title>
        <source>Acta Pharmacol Sin</source>
        <year>2020</year>
        <volume>41</volume>
        <fpage>138</fpage>
        <lpage>44</lpage>
        <pub-id pub-id-type="doi">10.1038/s41401-019-0228-6</pub-id>
        <?supplied-pmid 31263275?>
        <pub-id pub-id-type="pmid">31263275</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Gan</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>ZX</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting</article-title>
        <source>Nucleic Acids Res</source>
        <year>2022</year>
        <volume>50</volume>
        <fpage>W159</fpage>
        <lpage>64</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkac394</pub-id>
        <?supplied-pmid 35609983?>
        <pub-id pub-id-type="pmid">35609983</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Grimm</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Bu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>LigMate: a multifeature integration algorithm for ligand-similarity-based virtual screening</article-title>
        <source>J Chem Inf Model</source>
        <year>2020</year>
        <volume>60</volume>
        <fpage>6044</fpage>
        <lpage>53</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.9b01210</pub-id>
        <?supplied-pmid 33190499?>
        <pub-id pub-id-type="pmid">33190499</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Gan</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>ZX</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>FitDock: protein-ligand docking by template fitting</article-title>
        <source>Brief Bioinform</source>
        <year>2022</year>
        <volume>23</volume>
        <fpage>bbac087</fpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbac087</pub-id>
        <?supplied-pmid 35289358?>
        <pub-id pub-id-type="pmid">35289358</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Exploring the computational methods for protein-ligand binding site prediction</article-title>
        <source>Comput Struct Biotechnol J</source>
        <year>2020</year>
        <volume>18</volume>
        <fpage>417</fpage>
        <lpage>26</lpage>
        <pub-id pub-id-type="doi">10.1016/j.csbj.2020.02.008</pub-id>
        <?supplied-pmid 32140203?>
        <pub-id pub-id-type="pmid">32140203</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sabe</surname>
            <given-names>VT</given-names>
          </name>
          <name>
            <surname>Ntombela</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Jhamba</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Maguire</surname>
            <given-names>GEM</given-names>
          </name>
          <name>
            <surname>Govender</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Naicker</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: a review</article-title>
        <source>Eur J Med Chem</source>
        <year>2021</year>
        <volume>224</volume>
        <fpage>113705</fpage>
        <pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113705</pub-id>
        <?supplied-pmid 34303871?>
        <pub-id pub-id-type="pmid">34303871</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures</article-title>
        <source>J Med Chem</source>
        <year>2004</year>
        <volume>47</volume>
        <fpage>2977</fpage>
        <lpage>80</lpage>
        <pub-id pub-id-type="doi">10.1021/jm030580l</pub-id>
        <?supplied-pmid 15163179?>
        <pub-id pub-id-type="pmid">15163179</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Morris</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Huey</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Lindstrom</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Sanner</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Belew</surname>
            <given-names>RK</given-names>
          </name>
          <name>
            <surname>Goodsell</surname>
            <given-names>DS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</article-title>
        <source>J Comput Chem</source>
        <year>2009</year>
        <volume>30</volume>
        <fpage>2785</fpage>
        <lpage>91</lpage>
        <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id>
        <?supplied-pmid 19399780?>
        <pub-id pub-id-type="pmid">19399780</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Feinstein</surname>
            <given-names>WP</given-names>
          </name>
          <name>
            <surname>Brylinski</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Calculating an optimal box size for ligand docking and virtual screening against experimental and predicted binding pockets</article-title>
        <source>J Cheminform</source>
        <year>2015</year>
        <volume>7</volume>
        <fpage>18</fpage>
        <pub-id pub-id-type="doi">10.1186/s13321-015-0067-5</pub-id>
        <?supplied-pmid 26082804?>
        <pub-id pub-id-type="pmid">26082804</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Eberhardt</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Santos-Martins</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Tillack</surname>
            <given-names>AF</given-names>
          </name>
          <name>
            <surname>Forli</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings</article-title>
        <source>J Chem Inf Model</source>
        <year>2021</year>
        <volume>61</volume>
        <fpage>3891</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.1c00203</pub-id>
        <?supplied-pmid 34278794?>
        <pub-id pub-id-type="pmid">34278794</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rose</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Bradley</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Valasatava</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Duarte</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Prlic</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rose</surname>
            <given-names>PW</given-names>
          </name>
        </person-group>
        <article-title>NGL viewer: web-based molecular graphics for large complexes</article-title>
        <source>Bioinformatics</source>
        <year>2018</year>
        <volume>34</volume>
        <fpage>3755</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bty419</pub-id>
        <?supplied-pmid 29850778?>
        <pub-id pub-id-type="pmid">29850778</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wishart</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Feunang</surname>
            <given-names>YD</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Lo</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Marcu</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Grant</surname>
            <given-names>JR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>
        <source>Nucleic Acids Res</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D1074</fpage>
        <lpage>82</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>
        <?supplied-pmid 29126136?>
        <pub-id pub-id-type="pmid">29126136</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Shoichet</surname>
            <given-names>BK</given-names>
          </name>
          <name>
            <surname>Irwin</surname>
            <given-names>JJ</given-names>
          </name>
        </person-group>
        <article-title>Benchmarking sets for molecular docking</article-title>
        <source>J Med Chem</source>
        <year>2006</year>
        <volume>49</volume>
        <fpage>6789</fpage>
        <lpage>801</lpage>
        <pub-id pub-id-type="doi">10.1021/jm0608356</pub-id>
        <?supplied-pmid 17154509?>
        <pub-id pub-id-type="pmid">17154509</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mysinger</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Carchia</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Irwin</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Shoichet</surname>
            <given-names>BK</given-names>
          </name>
        </person-group>
        <article-title>Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking</article-title>
        <source>J Med Chem</source>
        <year>2012</year>
        <volume>55</volume>
        <fpage>6582</fpage>
        <lpage>94</lpage>
        <pub-id pub-id-type="doi">10.1021/jm300687e</pub-id>
        <?supplied-pmid 22716043?>
        <pub-id pub-id-type="pmid">22716043</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rohrer</surname>
            <given-names>SG</given-names>
          </name>
          <name>
            <surname>Baumann</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Maximum unbiased validation (MUV) data sets for virtual screening based on PubChem bioactivity data</article-title>
        <source>J Chem Inf Model</source>
        <year>2009</year>
        <volume>49</volume>
        <fpage>169</fpage>
        <lpage>84</lpage>
        <pub-id pub-id-type="doi">10.1021/ci8002649</pub-id>
        <?supplied-pmid 19434821?>
        <pub-id pub-id-type="pmid">19434821</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Triballeau</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Acher</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Brabet</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Pin</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Bertrand</surname>
            <given-names>HO</given-names>
          </name>
        </person-group>
        <article-title>Virtual screening workflow development guided by the “receiver operating characteristic” curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4</article-title>
        <source>J Med Chem</source>
        <year>2005</year>
        <volume>48</volume>
        <fpage>2534</fpage>
        <lpage>47</lpage>
        <pub-id pub-id-type="doi">10.1021/jm049092j</pub-id>
        <?supplied-pmid 15801843?>
        <pub-id pub-id-type="pmid">15801843</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Durrant</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>McCammon</surname>
            <given-names>JA</given-names>
          </name>
        </person-group>
        <article-title>NNScore 2.0: a neural-network receptor-ligand scoring function</article-title>
        <source>J Chem Inf Model</source>
        <year>2011</year>
        <volume>51</volume>
        <fpage>2897</fpage>
        <lpage>903</lpage>
        <pub-id pub-id-type="doi">10.1021/ci2003889</pub-id>
        <?supplied-pmid 22017367?>
        <pub-id pub-id-type="pmid">22017367</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lucido</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Orlando</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Vecchio</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Malkowski</surname>
            <given-names>MG</given-names>
          </name>
        </person-group>
        <article-title>Crystal structure of aspirin-acetylated human cyclooxygenase-2: insight into the formation of products with reversed stereochemistry</article-title>
        <source>Biochemistry</source>
        <year>2016</year>
        <volume>55</volume>
        <fpage>1226</fpage>
        <lpage>38</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.biochem.5b01378</pub-id>
        <?supplied-pmid 26859324?>
        <pub-id pub-id-type="pmid">26859324</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rao</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Knaus</surname>
            <given-names>EE</given-names>
          </name>
        </person-group>
        <article-title>Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond</article-title>
        <source>J Pharm Pharm Sci</source>
        <year>2008</year>
        <volume>11</volume>
        <fpage>81s</fpage>
        <lpage>110s</lpage>
        <pub-id pub-id-type="doi">10.18433/J3T886</pub-id>
        <?supplied-pmid 19203472?>
        <pub-id pub-id-type="pmid">19203472</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sharma</surname>
            <given-names>JN</given-names>
          </name>
          <name>
            <surname>Jawad</surname>
            <given-names>NM</given-names>
          </name>
        </person-group>
        <article-title>Adverse effects of COX-2 inhibitors</article-title>
        <source>ScientificWorldJournal</source>
        <year>2005</year>
        <volume>5</volume>
        <fpage>629</fpage>
        <lpage>45</lpage>
        <pub-id pub-id-type="doi">10.1100/tsw.2005.82</pub-id>
        <?supplied-pmid 16113940?>
        <pub-id pub-id-type="pmid">16113940</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>ZW</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>LP</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>JP</given-names>
          </name>
        </person-group>
        <article-title>Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development</article-title>
        <source>Curr Med Chem</source>
        <year>2009</year>
        <volume>16</volume>
        <fpage>3480</fpage>
        <lpage>675</lpage>
        <pub-id pub-id-type="doi">10.2174/092986709789057635</pub-id>
        <?supplied-pmid 19515014?>
        <pub-id pub-id-type="pmid">19515014</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vargesson</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Thalidomide-induced teratogenesis: history and mechanisms</article-title>
        <source>Birth Defects Res C Embryo Today</source>
        <year>2015</year>
        <volume>105</volume>
        <fpage>140</fpage>
        <lpage>56</lpage>
        <pub-id pub-id-type="doi">10.1002/bdrc.21096</pub-id>
        <?supplied-pmid 26043938?>
        <pub-id pub-id-type="pmid">26043938</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Lian</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents</article-title>
        <source>Nucleic Acids Res</source>
        <year>2022</year>
        <volume>50</volume>
        <fpage>D1398</fpage>
        <lpage>407</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkab953</pub-id>
        <?supplied-pmid 34718717?>
        <pub-id pub-id-type="pmid">34718717</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Biamonte</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Van de Water</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Arndt</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>Scannevin</surname>
            <given-names>RH</given-names>
          </name>
          <name>
            <surname>Perret</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>WC</given-names>
          </name>
        </person-group>
        <article-title>Heat shock protein 90: inhibitors in clinical trials</article-title>
        <source>J Med Chem</source>
        <year>2010</year>
        <volume>53</volume>
        <fpage>3</fpage>
        <lpage>17</lpage>
        <pub-id pub-id-type="doi">10.1021/jm9004708</pub-id>
        <?supplied-pmid 20055425?>
        <pub-id pub-id-type="pmid">20055425</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bissantz</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Folkers</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Rognan</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations</article-title>
        <source>J Med Chem</source>
        <year>2000</year>
        <volume>43</volume>
        <fpage>4759</fpage>
        <lpage>67</lpage>
        <pub-id pub-id-type="doi">10.1021/jm001044l</pub-id>
        <?supplied-pmid 11123984?>
        <pub-id pub-id-type="pmid">11123984</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Lai</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Further development and validation of empirical scoring functions for structure-based binding affinity prediction</article-title>
        <source>J Comput Aided Mol Des</source>
        <year>2002</year>
        <volume>16</volume>
        <fpage>11</fpage>
        <lpage>26</lpage>
        <pub-id pub-id-type="doi">10.1023/A:1016357811882</pub-id>
        <?supplied-pmid 12197663?>
        <pub-id pub-id-type="pmid">12197663</pub-id>
      </element-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Sze</surname>
            <given-names>KH</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ballester</surname>
            <given-names>PJ</given-names>
          </name>
        </person-group>
        <article-title>Machine-learning scoring functions for structure-based virtual screening</article-title>
        <source>Wiley Interdiscip Rev Comput Mol Sci</source>
        <year>2021</year>
        <volume>11</volume>
        <fpage>e1478</fpage>
        <pub-id pub-id-type="doi">10.1002/wcms.1478</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kuang</surname>
            <given-names>W</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information</article-title>
        <source>Nat Commun</source>
        <year>2017</year>
        <volume>8</volume>
        <fpage>573</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-017-00680-8</pub-id>
        <?supplied-pmid 28924171?>
        <pub-id pub-id-type="pmid">28924171</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zeng</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Target identification among known drugs by deep learning from heterogeneous networks</article-title>
        <source>Chem Sci</source>
        <year>2020</year>
        <volume>11</volume>
        <fpage>1775</fpage>
        <lpage>97</lpage>
        <pub-id pub-id-type="doi">10.1039/C9SC04336E</pub-id>
        <?supplied-pmid 34123272?>
        <pub-id pub-id-type="pmid">34123272</pub-id>
      </element-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Accelerating AutoDock Vina with GPUs</article-title>
        <source>Molecules</source>
        <year>2022</year>
        <volume>27</volume>
        <fpage>3041</fpage>
        <pub-id pub-id-type="doi">10.3390/molecules27093041</pub-id>
        <?supplied-pmid 35566391?>
        <pub-id pub-id-type="pmid">35566391</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
